Analyst consensus rating
Sunshine Biopharma Analyst Rating: none
Direct answer
Sunshine Biopharma's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $56.00.
Forecast evidence checked October 17, 2026.
Get free Sunshine Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.22
- Average price target
- $56.00
- High price target
- $56.00
- Low price target
- $56.00
- Low target gap
- +25,148%
- Target upside
- +25,148%
- High target gap
- +25,148%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Sunshine Biopharma?
Sunshine Biopharma has a verified none consensus. The same dataset has an average price target of $56.00.
How far are Sunshine Biopharma's low and high targets from the recorded price?
The low target implies +25,148%, while the high target implies +25,148%.
How many analysts are included in Sunshine Biopharma's consensus?
The verified consensus includes 1 analysts.
How is Sunshine Biopharma's target upside or downside calculated?
The average target of $56.00 is divided by the recorded price of $0.22, then one is subtracted to produce +25,148%. This does not guarantee a future return.
When was Sunshine Biopharma's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.